A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

PHASE3CompletedINTERVENTIONAL

Enrollment

677

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

June 30, 2002

Study Completion Date

June 30, 2002

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Rebif®

Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.

DRUG

Avonex®

Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.